금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
EU Locks In Plan To Triple Energy Storage Capacity By 2030
Europe desperately needs an energy storage revolution. As the region gets rocked by the third energy...
Oil Traders Stay Bearish Despite Deepening Middle East Disruptions
Despite continued hostilities in the Middle East and an expansion of the war to the Red Sea, oil tra...
S&P closes at record high as soft jobs report eases rate-hike concerns
STORY: U.S. stocks rallied on Friday, with the Dow gaining more than a quarter of a percent, the S&P...
NRP plans to raise distributions significantly in November as debt falls to $14M
Par Pacific expects Q3 midpoint throughput of 182,000 barrels per day following Hawaii turnaround
CorVel signals disciplined execution as it expands AI workflows and launches executive advisory services
Michael Burry Sends Stark Warning on S&P 500 Crash
Michael Burry sounds the alarm on a 1987-style selloff despite fresh market highs
Michael Burry Drops Shocking Take on AI Stocks
Calm markets may be encouraging investors to take greater risks
Alphabet’s stock drops as Google loses another key AI executive
Jeff Dean, Google’s chief scientist and one of its company’s first employees, is leaving to launch his own company.
4 Things All Dividend Investors Need to Know About Building Passive Income Right Now
Follow these guidelines and you'll be on your way to building a durable and sustainable long-term income stream.
Is Conagra Stock Worth Buying as Low Valuation Meets Weak Growth?
Conagra's low valuation offers downside support, but falling sales, margins and earnings keep its fiscal 2027 reset-and buy case-under pressure.
Crude oil prices ease losses after Houthis say they attacked Saudi tanker
FTI Consulting Stock Declines 4.1% Since Q2 Earnings Beat
FCN beats second-quarter earnings estimates and reaffirms revenue guidance. Its rising costs squeeze margins and send shares lower.
Warren Buffett Just Issued a Blunt Warning About the Stock Market. History Is Clear About What Comes Next.
The wrong strategy could be particularly costly right now.
Bristol-Myers falls on report there are no talks going on with AstraZeneca